AAAAAA

   
Results: 1-16 |
Results: 16
TREATMENT OF CANCER CHEMOTHERAPY-INDUCED TOXICITY WITH THE PINEAL HORMONE MELATONIN
Authors: LISSONI P TANCINI G BARNI S PAOLOROSSI F ARDIZZOIA A CONTI A MAESTRONI G
Citation: P. Lissoni et al., TREATMENT OF CANCER CHEMOTHERAPY-INDUCED TOXICITY WITH THE PINEAL HORMONE MELATONIN, Supportive care in cancer, 5(2), 1997, pp. 126-129
A RANDOMIZED STUDY OF CHEMOTHERAPY WITH CISPLATIN PLUS ETOPOSIDE VERSUS CHEMOENDOCRINE THERAPY WITH CISPLATIN, ETOPOSIDE AND THE PINEAL HORMONE MELATONIN AS A FIRST-LINE TREATMENT OF ADVANCED NONSMALL CELL LUNG-CANCER PATIENTS IN A POOR CLINICAL STATE
Authors: LISSONI P PAOLOROSSI F ARDIZZOIA A BARNI S CHILELLI M MANCUSO M TANCINI G CONTI A MAESTRONI GJM
Citation: P. Lissoni et al., A RANDOMIZED STUDY OF CHEMOTHERAPY WITH CISPLATIN PLUS ETOPOSIDE VERSUS CHEMOENDOCRINE THERAPY WITH CISPLATIN, ETOPOSIDE AND THE PINEAL HORMONE MELATONIN AS A FIRST-LINE TREATMENT OF ADVANCED NONSMALL CELL LUNG-CANCER PATIENTS IN A POOR CLINICAL STATE, Journal of pineal research, 23(1), 1997, pp. 15-19
ANTICANCER NEUROIMMUNOMODULATION BY PINEAL HORMONES OTHER THAN MELATONIN - PRELIMINARY PHASE-II STUDY OF THE PINEAL INDOLE 5-METHOXYTRYPTOPHOL IN ASSOCIATION WITH LOW-DOSE IL-2 AND MELATONIN
Authors: LISSONI P FUMAGALLI L PAOLOROSSI F ROVELLI F ROSELLI MG MAESTRONI GJM
Citation: P. Lissoni et al., ANTICANCER NEUROIMMUNOMODULATION BY PINEAL HORMONES OTHER THAN MELATONIN - PRELIMINARY PHASE-II STUDY OF THE PINEAL INDOLE 5-METHOXYTRYPTOPHOL IN ASSOCIATION WITH LOW-DOSE IL-2 AND MELATONIN, Journal of biological regulators and homeostatic agents, 11(3), 1997, pp. 119-122
IS THERE A ROLE FOR MELATONIN IN THE TREATMENT OF NEOPLASTIC CACHEXIA
Authors: LISSONI P PAOLOROSSI F TANCINI G BARNI S ARDIZZOIA A BRIVIO F ZUBELEWICZ B CHATIKHINE V
Citation: P. Lissoni et al., IS THERE A ROLE FOR MELATONIN IN THE TREATMENT OF NEOPLASTIC CACHEXIA, European journal of cancer, 32A(8), 1996, pp. 1340-1343
A PHASE-II STUDY OF TAMOXIFEN PLUS MELATONIN IN METASTATIC SOLID TUMOR PATIENTS
Authors: LISSONI P PAOLOROSSI F TANCINI G ARDIZZOIA A BARNI S BRIVIO F MAESTRONI GJM CHILELLI M
Citation: P. Lissoni et al., A PHASE-II STUDY OF TAMOXIFEN PLUS MELATONIN IN METASTATIC SOLID TUMOR PATIENTS, British Journal of Cancer, 74(9), 1996, pp. 1466-1468
A RANDOMIZED STUDY OF TAMOXIFEN ALONE VERSUS TAMOXIFEN PLUS MELATONININ ESTROGEN RECEPTOR-NEGATIVE HEAVILY PRETREATED METASTATIC BREAST-CANCER PATIENTS
Authors: LISSONI P ARDIZZOIA A BARNI S PAOLOROSSI F TANCINI G MEREGALLI S ESPOSTI D ZUBELEWICZ B BRACZOWSKI R
Citation: P. Lissoni et al., A RANDOMIZED STUDY OF TAMOXIFEN ALONE VERSUS TAMOXIFEN PLUS MELATONININ ESTROGEN RECEPTOR-NEGATIVE HEAVILY PRETREATED METASTATIC BREAST-CANCER PATIENTS, Oncology Reports, 2(5), 1995, pp. 871-873
TREATMENT OF INTERFERON-ALPHA 2A(IFN)-INDUCED THROMBOCYTOPENIA BY THEPINEAL NEUROHORMONE MELATONIN (MTL)
Authors: LISSONI P BARNI S TANCINI G ADIZZOIA A PAOLOROSSI F
Citation: P. Lissoni et al., TREATMENT OF INTERFERON-ALPHA 2A(IFN)-INDUCED THROMBOCYTOPENIA BY THEPINEAL NEUROHORMONE MELATONIN (MTL), European journal of cancer, 31A, 1995, pp. 583-583
PRESERVATION OF THE ORGAN IN THE THERAPY OF INFILTRATING BLADDER-TUMORS
Authors: ROCCO F SCANDINO E CARMIGNANI L DECOBELLI O ANDRES M CRISPINO S TANCINI G PAOLOROSSI F BOYLE P MAISONNEUVE P
Citation: F. Rocco et al., PRESERVATION OF THE ORGAN IN THE THERAPY OF INFILTRATING BLADDER-TUMORS, European journal of cancer, 31A, 1995, pp. 1154-1154
CLINICAL EFFICACY OF CANCER SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 IN RELATION TO THE PRETREATMENT LEVELS OF TUMOR-GROWTH FACTOR INSULIN-LIKE GROWTH-FACTOR-I
Authors: LISSONI P BARNI S ARDIZZOIA A FRIGERIO F PAOLOROSSI F CAZZANIGA M TANCINI G ROCCO F AAPRO M
Citation: P. Lissoni et al., CLINICAL EFFICACY OF CANCER SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 IN RELATION TO THE PRETREATMENT LEVELS OF TUMOR-GROWTH FACTOR INSULIN-LIKE GROWTH-FACTOR-I, Tumori, 81(4), 1995, pp. 261-264
2ND-LINE THERAPY WITH INTERFERON-ALPHA PLUS VINBLASTINE IN METASTATICRENAL-CELL CANCER-PATIENTS PROGRESSED UNDER INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY
Authors: PAOLOROSSI F VILLA S BARNI S TANCINI G ANDRES M LISSONI P
Citation: F. Paolorossi et al., 2ND-LINE THERAPY WITH INTERFERON-ALPHA PLUS VINBLASTINE IN METASTATICRENAL-CELL CANCER-PATIENTS PROGRESSED UNDER INTERLEUKIN-2 SUBCUTANEOUS IMMUNOTHERAPY, Tumori, 81(1), 1995, pp. 45-47
WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS
Authors: LISSONI P BARNI S ARDIZZOIA A FOSSATI V PAOLOROSSI F TANCINI G
Citation: P. Lissoni et al., WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS, Journal of biological regulators and homeostatic agents, 8(2), 1994, pp. 53-55
WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS
Authors: LISSONI P BARNI S ARDIZZOIA A FOSSATI V PAOLOROSSI F TANCINI G
Citation: P. Lissoni et al., WEEKLY EPIRUBICIN PLUS LOW-DOSE INTERLEUKIN-2 SUBCUTANEOUS THERAPY INBREAST-CANCER - PRELIMINARY IMMUNOBIOLOGICAL RESULTS, Journal of biological regulators and homeostatic agents, 8(2), 1994, pp. 53-55
A RANDOMIZED STUDY OF IMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN VS CHEMOTHERAPY WITH CISPLATIN AND ETOPOSIDE CISPLATIN AND ETOPOSIDE AS FIRST-LINE
Authors: LISSONI P MEREGALLI S FOSSATI V PAOLOROSSI F BARNI S TANCINI G FRIGERIO F
Citation: P. Lissoni et al., A RANDOMIZED STUDY OF IMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN VS CHEMOTHERAPY WITH CISPLATIN AND ETOPOSIDE CISPLATIN AND ETOPOSIDE AS FIRST-LINE, Tumori, 80(6), 1994, pp. 464-467
PROGNOSTIC FACTORS OF THE CLINICAL-RESPONSE TO SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 ALONE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: LISSONI P BARNI S ARDIZZOIA A CRISPINO S PAOLOROSSI F ANDRES M SCARDINO E TANCINI G
Citation: P. Lissoni et al., PROGNOSTIC FACTORS OF THE CLINICAL-RESPONSE TO SUBCUTANEOUS IMMUNOTHERAPY WITH INTERLEUKIN-2 ALONE IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, Oncology, 51(1), 1994, pp. 59-62
RESPIRATORY-DISTRESS SYNDROME IN PATIENTS WITH ADVANCED CANCER TREATED WITH PENTOXIFYLLINE - A RANDOMIZED STUDY
Authors: ARDIZZOIA A LISSONI P TANCINI G PAOLOROSSI F CRISPINO S VILLA S BARNI S
Citation: A. Ardizzoia et al., RESPIRATORY-DISTRESS SYNDROME IN PATIENTS WITH ADVANCED CANCER TREATED WITH PENTOXIFYLLINE - A RANDOMIZED STUDY, Supportive care in cancer, 1(6), 1993, pp. 331-333
A WEEKLY SCHEDULE OF EPIRUBICIN IN PRETREATED ADVANCED BREAST-CANCER
Authors: BARNI S ARCHILI C LISSONI P PAOLOROSSI F CRISPINO S TANCINI G
Citation: S. Barni et al., A WEEKLY SCHEDULE OF EPIRUBICIN IN PRETREATED ADVANCED BREAST-CANCER, Tumori, 79(1), 1993, pp. 45-48
Risultati: 1-16 |